Longeviti Introduces Brain Ultrasound Interface 

July 7, 2026 — Longeviti Neuro Solutions has launched two strategic initiatives, ClearFit AI, a Brain Ultrasound Interface (BUI). These technologies create a persistent acoustic interface to the brain, enabling real-time bedside imaging and supporting future advances in neurosurgical care.

The ClearFit AI platform combines:

• ClearFit sonolucent cranial implants

• Ultrasound compatibility

• Clinical workflow and training support

• AI-enhanced imaging

This platform enables the Brain Ultrasound Interface — a new category of post-operative neuro access that may reduce reliance on CT and MRI transport, integrate into existing neuro workflows, and position the implant site as a potential foundation for future applications currently under investigation.

Operational and Economic Potential

As healthcare systems continue to evaluate scalable and cost-conscious technologies, ultrasound-enabled imaging approaches may offer operational advantages in select care environments.

Adjunct imaging technologies may contribute to:

• Expanded bedside visualization capabilities

• Reduce operational transport burdens

• Increased accessibility to imaging technologies

• Imaging workflow efficiency and process optimization

Any future clinical, operational, or economic benefits will depend on regulatory review, validation activities, adoption patterns and real-world implementation.

Beyond the Implant

For clinicians, BUI means the ability to assess the brain at the bedside — possibly reducing operational burdens such as scheduling imaging, transporting a post-operative patient, or waiting for results. ClearFit AI makes that possible by turning the implant site into a persistent sonolucent interface, with AI-assisted imaging optimization only available on Clarius Ultrasound units.

For patients, that access may mean fewer trips to the scanner, less radiation exposure and bedside visualization that may extend from the ICU into outpatient and recovery settings.

“The mission was always in the name,” said Jesse Christopher, CEO. “Longeviti exists to pursue scalable platform technologies that help create new possibilities for clinicians, researchers, and patients while supporting the broader goal of protecting cognitive function and improving quality of life.”